AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.20
+0.06 (1.17%)
May 22, 2026, 4:00 PM EDT - Market closed

AbCellera Biologics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-143.96-146.41-162.86-146.4158.52153.46
Depreciation & Amortization
30.8728.829730.8933.117.25
Stock-Based Compensation
53.0255.7967.5864.1849.4830.65
Other Adjustments
1.71.2-84.44-5.786.431.55
Change in Receivables
6.84-55.62-75.12-45.93106.4622.48
Changes in Accounts Payable
-2.543.4610.64-15.1-2.09-3.24
Changes in Income Taxes Payable
-31.02-29.846.6530.46-88.61-13.53
Changes in Unearned Revenue
-28.32-5.8326.0425.5515.4539.34
Changes in Other Operating Activities
8.0917.155.9518.25-1.38-3.38
Operating Cash Flow
-153.26-131.3-108.56-43.88277.36244.58
Operating Cash Flow Growth
----13.40%977.94%
Capital Expenditures
-35.97-42.77-78.4-76.95-70.66-58.45
Purchases of Intangible Assets
-----2-
Purchases of Investments
-442.28-443.18-784.71-1,035-789.66-305.03
Proceeds from Sale of Investments
459.85506.07937.88910.94510.6327.61
Payments for Business Acquisitions
------11.46
Other Investing Activities
10.0967.6346.64-19.9-0.9415.09
Investing Cash Flow
54.7387.75121.41-221.11-352.63-332.25
Other Financing Activities
19.8314.0812.7710.36-1.63-3.89
Financing Cash Flow
15.314.0812.7710.36-1.63-3.89
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.471.1-2.620.59-9.6-1.43
Net Cash Flow
-82.76-28.3723.01-254.04-86.49-92.97
Free Cash Flow
-189.23-174.07-186.95-120.82206.7186.13
Free Cash Flow Growth
----11.05%1329.91%
FCF Margin
-238.91%-231.69%-648.40%-317.75%42.58%49.61%
Free Cash Flow Per Share
-0.63-0.58-0.64-0.420.660.58
Levered Free Cash Flow
-193.89-175.43-94.98-133.2944.33131.46
Unlevered Free Cash Flow
-218.98-208.01-187.93-186.4429.35121.14
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q